Presentation is loading. Please wait.

Presentation is loading. Please wait.

To be, or well be, II Teknologiat osana palveluprosessin muutosta

Similar presentations

Presentation on theme: "To be, or well be, II Teknologiat osana palveluprosessin muutosta"— Presentation transcript:

1 To be, or well be, II Teknologiat osana palveluprosessin muutosta
Jaana Tuominen, GE Healthcare

2 GE Healthcare

3 GE Healthcare: A Unique Collection of Expertise…
Technologies Bio-Sciences Information Technology Imaging and Intervention Molecular Diagnostics We have the skills, talent, science and technology to understand all of these key areas of healthcare. It’s a unique collection of competencies, built through organic growth and acquisitions over the last 8-10 years. We can use our skills in chemistry, physics and engineering to introduce interventional skills for better diagnosis. We can use our skills to look at molecular diagnostics to create gene chips with 56,000 genes. We can use our skills to understand the pharmaceutical revolution, the need to develop smarter segmented portfolios and how we help people capture that data and help them innovate in healthcare. Pharmaceutical Solutions …creating advanced diagnostics

4 Need a fundamental change …
Cancer Heart Disease Brain Disorders Advanced disease states affect many people. For example, one out of every three people in the world will have cancer in their lifetime. Almost 50% of people die after their first heart attack. And 20% of people experience brain or neurological disorders between the ages of 75 and 84. Cancer, heart disease and neurology will be the three key areas that GE Healthcare will focus on. There will always be an urgent imperative to change healthcare to provide greater patient benefits. But what’s unique about “now’” is that we have enough information -- powered by advances in computing -- coupled with increased understanding of biology at the molecular level, to effect a fundamental change. One person in three will have cancer 50% die after 1st heart attack 20% aged suffer from Alzheimer’s disease

5 21st Century Personalized Healthcare
A new age of medicine 21st Century Personalized Healthcare Build 1 In today’s model of medicine, in which we “find” and “treat,” there are opportunities for dramatic gains in disease diagnosis and treatment. Build 2 However, in the new paradigm of personalized medicine, diagnostic tests will become increasingly important in detecting disease, selecting treatment, and also monitoring and tracking therapy. In addition, knowledge of genetic predisposition to disease will shift medicine increasingly towards prediction and prevention. Predict Diagnose Inform Treat

6 it may never appear here.
If we can detect it here, it may never appear here. Predict. Diagnose. Inform. Treat. By understanding disease processes at the molecular level, GE Healthcare is helping researchers push the boundaries of discovery. Paving the path for breakthroughs that will profoundly affect the ways in which we can manage our health today and in the future. Armed with GE Healthcare products, technologies and capabilities, physicians will be better able to pinpoint and diagnose disease sooner. Scientists and researchers from academia to industry will be better able to understand disease and develop new drugs more quickly. Pharmaceutical companies will be better able to manufacture medicines that treat disease more precisely and effectively. So that patients may receive care that’s specifically tailored to their needs.

7 Predict See the future. Change the future.
Molecular understanding of diseases A new generation of diagnostics Identify the “genetic fingerprints” of disease Predict disease before the onset See the future. Change the future. From birth, we each have a unique genetic code that can reveal the secrets of our future health. The vision: identify people who have a greater chance of developing a specific disease – even before symptoms appear – using genetic profiling. Simple blood tests. And a whole new generation of non-invasive molecular imaging tools. Then take steps to prevent that disease from ever affecting them. Armed with new life sciences tools developed by GE Healthcare, researchers will be better able to identify “genetic fingerprints” of specific diseases that predict how those diseases are likely to develop, how quickly they will progress – and what we can do to prevent them. In the near future, using GE Healthcare technology, physicians will be able to follow, in real time, a patient’s response to therapy – allowing a physician to determine if a therapy is working and, if it’s not, change the therapy. Closely monitor at-risk patients. Provide lifestyle advice or curative treatment at an early stage, when therapies are most effective. And patients will be better able to make decisions about their own health – long before there’s any sign of a disease.

8 Diagnose The earlier you detect disease, the earlier you can deal with it. Transformational medical imaging and medical diagnostics Visualize and analyze disease at a molecular level Diagnose disease more precisely – based on the individual patient Improve patient outcomes The earlier you detect disease, even before symptoms exist, the earlier you can deal with it. And improve the chances of a successful outcome for the patient. GE Healthcare combines advanced, optimized diagnostic imaging systems with market-leading contrast agents and radiopharmaceuticals that produce images of the human body that are clear and incredibly detailed. Making it easier for physicians to identify disease and its specific location. Diagnose earlier and more accurately. Better predict outcomes. In years to come, molecular-based diagnostic tests will sharpen clinical precision in profiling disease, selecting treatments, and monitoring and tracking therapies. Diagnosing disease even before it becomes apparent and delivering the right treatment, prescribed for the right patient, at the right time with the right outcome is only possible with early and accurate diagnosis.

9 Inform Enable better care through molecular knowledge.
Provide life-critical patient information – when, where and how it’s needed Empower through information about “genetic signatures” Tailor treatment to the patient Monitor and manage the efficacy of personalized therapy Predict the likelihood of developing a heart attack years before it would otherwise occur. Identify the cellular signature for the debilitating progression of Alzheimer’s disease, and use that signature to follow the response to therapy. Determine the precise stage of an HIV infection – then treat it with the specific drugs designed for maximum effectiveness. Information such as this, critical to the patient’s care, will become increasingly detailed, commonplace and available as together we expand our body of molecular knowledge. Utilizing technologies from GE Healthcare, molecular imaging already enables physicians to better diagnose disease and track its treatment. Diagnostic procedures such as PET or MRI help to confirm the presence of disease, monitor its progress and gauge a patient’s response to therapy. So clinicians can verify that treatment is working within days, rather than waiting weeks. Our growing capabilities in information technologies will also help enable the smooth, seamless linking of critical data and information from gene to diagnosis to treatment – and allow patients to make more fully informed decisions about their treatment and lifestyle options.

10 Treat Read the genes. Tailor the treatment.
Understand disease at a molecular level Develop more targeted and effective therapies Enable the development of new, more targeted drugs… faster Read the genes. And tailor the treatment. The growing understanding of disease at the molecular level – fueled by GE Healthcare – will help yield more targeted and more effective therapies. Physicians will be better able to select the best drug for every patient, and rule out therapies that are likely not to be as effective. From side effects to outcomes, each patient’s response to treatment may be more accurately predicted. Our technologies today help pharmaceutical companies cut the time and cost of finding and developing new drugs. Turn research into full-scale manufacturing quickly and easily. Develop diagnostics and targeted therapeutics in tandem. And better select those drug development candidates capable of becoming effective and safe medicines.

11 GE Healthcare Vision At GE Healthcare, We Strive to See Life More Clearly We Help Predict, Diagnose, Inform and Treat So That Every Individual Can Live Life to the Fullest At GE Healthcare, we strive to see life more clearly, helping customers to better understand disease, and diagnose and treat patients so that every individual can live life to the fullest. Broadly speaking, we are working on improving the quality of life dramatically through this process. No matter where you sit on the healthcare value chain, you can see the need for fundamental changes.

12 The Emerging Era of Chronic Disease

13 Response Needed for a New Era
Era of Infectious Disease Care Era of Acute Care Era of Chronic Care Era of Chronic Care requires collection and management of patient medical information outside of the traditional hospital setting.

14 Population Managing Multiple Diseases
Medical progress often turns an acute condition into a chronic one. Ex: 40% decline in mortality from coronary heart disease since 1980, but more people are living with survival effects. A chronic condition lasts more than one year, limits a patient’s abilities and requires ongoing care. Chronic conditions include: Cardiovascular disease Diabetes Hypertension End-stage renal disease (ESRD) Chronic obstructive pulmonary disease (COPD) Osteoporosis Arthritis Some types of cancers Asthma Neurodegenerative disorders (Alzheimer’s, Parkinson’s, etc.) Chronic pain Stroke and other brain injuries

15 Chronic Health Impact Pending Dr. & RN Shortage
Rising Costs of Healthcare US Supply & Demand for Registered Nurses Patients With Chronic Conditions Account For: Demand 55% 66% 96% 60% Supply 80% Quality of Care Dilemma Medicare Expenditures Per # of Chronic Conditions 60 Million Americans with 1 Chronic Disease 157 Million Americans with 1 by 2020 Medicare Insolvency by 2019 Direct Costs $510 Billion, to $1.07 Trillion, 2020 80% of Healthcare Costs on 20% of Population Chronic consuming 70% of Prescription Drugs

16 Ambulatory Care – to address chronic diseases

17 Ambulatory Care + Address Key Disease States… Ambulatory Monitoring…
Source: 2004 S1 Slide Address Key Disease States… Ambulatory Monitoring… Enables early intervention Improves patient outcomes Reduces hospitalization costs Increases Cost Savings Increases patient compliance Improves provider productivity Improves quality of life Congestive Heart Failure Chronic patient, managed at home + Asthma and COPD MSU Telehealth Case Study: Ambulatory Monitoring Solution reduced… Total Bed Utilization  55% CHF Patient Hospital Utilization  43% Urgent Care Visits  35% Ambulatory diagnostic device + connection to physician & EMR Therapeutic dose monitoring

18 Market Drivers Aging population
Acute conditions  chronic conditions Acute intervention  managed care Increasing patient consumerism - “Worried well” Need for cost reductions in healthcare systems Changes in reimbursement to encourage outpatient care Improvement in communications access (Source: F&S 2004 US RPM)

19 Market Restraints High cost and inflexibility of products
Limited scope of reimbursement Documentation of outcomes Legal issues (e.g. state licensure issues) Lack of standardization of clinical protocols Privacy concerns Tight budgets with home health care Lack of physician acceptance (Source: F&S 2004 US RPM)

20 Product Needs Low cost Flexibility
Key CHF Parameters… Weight SPO2 ECG Heart Rhythm Product Needs Blood Pressure Drug Compliance Activity Level Nutrition/Diet Low cost Flexibility Ease of Use (single button, voice prompts) Unbreakable Designed for home environment Communications requirements

21 Remote Patient Monitoring Overview
Physician Configured Patient Alertee (e.g., FNP) Data Data alert Home hub Central platform Algorithm Results EMR/ Patient dashboard Professional caregivers Data PC/TV Data Non-professional caregivers Sensing Pre-prosessing Network / Data Data management Information interface Customer interface Non-invasive sensors Novel Parameters Drug Compliance Smart alerts Wireless platform Information portal Telecommunication Novel algorithms, modeling Existing algorithms Decision Support Configurable Alerts EMR Integration Patient Access Patient Triage Educate Patient Engage Family

22 Remote monitoring and viewing – opportunities in the near future

23 The story of Joe Doe 14:32:23 14:32:28
RN M. Smith receives the ‘ST high’ alarm in her PDA. She checks the snapshot, acknowledges the message and hurries to the patient. Telemetry patient John Doe is going to have a cup of coffee in the hospital cafeteria.

24 14:33:32 14:33:55 The message shows the snapshot and RN Smith’s
request for advice After examination she decides to consult Dr. S. Jones who is the physician in charge of John Doe.

25 14:35:12 14:36:38 After looking at the John Doe’s snapshot and real-time and trended data, Dr. Jones gives care instructions to RN Smith RN Smith makes the lab test order electronically with her PDA

26 15:17:09 15:17:09 The lab results are ready and they are sent to Dr. Jones automatically by the system Dr. Jones makes the drug order with his PDA, and sends it to RN Smith

27 15:21:17 15:22:50 RN Smith receives the drug order and administers the drug in John Doe’s IV bag RN Smith documents the drug treatment utilizing the bar code scanner that is built-in her PDA



Download ppt "To be, or well be, II Teknologiat osana palveluprosessin muutosta"

Similar presentations

Ads by Google